Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 12Lung Neoplasms 12Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 7Breast Neoplasms 7Gliosarcoma 6Glioblastoma 6Salivary Gland Neoplasms 5Rectal Neoplasms 5Glioma 5Colorectal Neoplasms 5Colonic Neoplasms 5Astrocytoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Solid Tumors 4Esophageal Neoplasms 4Tongue Neoplasms 3Prostatic Neoplasms 3Oligodendroglioma 3Lymphoma 3Gallbladder Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Hepatocellular 3Bile Duct Neoplasms 3Advanced Cancers 3Advanced Cancer 3

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Erlotinib Hydrochloride × Clear all
NCT01515969 2016-07-12

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Stanford University

Phase 1 Terminated
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡